Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Jeffrey Colvin

Anesthesiology Lubbock, TX Medical Doctor

NPI 1750304473 CMS profile 1210264

4642 N Loop 289 Ste 209, Lubbock, TX 79416

Open in the dashboard

General payments

$8,357

237 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Jeffrey Colvin of Lubbock, TX is reported in the CMS Open Payments database as having received $8,357 across 237 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $900 33
2022 General $796 38
2021 General $3,524 83
2020 General $2,194 51
2019 General $942 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Colvin
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Jeffrey Colvin were reported at $0. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Jeffrey Colvin Anesthesiology median Middle half National median
2019 $942 $72 $23–$151 $163
2020 $2,194 $36 $17–$120 $114
2021 $3,524 $49 $21–$135 $132
2022 $796 $52 $22–$144 $149
2023 $900 $53 $23–$143 $160
2024 $0 $55 $25–$150 $164
2025 $0 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Spinal Simplicity, LLC $2,151 17 payments
  2. Boston Scientific Corporation $1,872 22 payments
  3. AbbVie, Inc. $615 25 payments
  4. Nevro Corp. $478 11 payments
  5. Biodelivery Sciences International, Inc. $427 35 payments
  6. Collegium Pharmaceutical, Inc. $413 26 payments
  7. Medtronic, Inc. $326 19 payments
  8. Biohaven Pharmaceutical Holding Company Ltd. $316 8 payments
  9. Medtronic USA, Inc. $297 19 payments
  10. Arbor Pharmaceuticals, Inc. $236 11 payments
  11. Other $1,227 44 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $5,486 230 payments
  2. Education $1,495 2 payments
  3. Travel and Lodging $1,376 5 payments
Products named General payments · program years 2019–2023
  1. HA MINUTEMAN G3-R $2,151 17 payments
  2. SUPERION Pain Management $1,602 14 payments
  3. UBRELVY $586 23 payments
  4. NURTEC ODT $418 9 payments
  5. BELBUCA $414 34 payments
  6. Senza Spinal Cord Stimulation System $244 6 payments
  7. INTELLIS $223 13 payments
  8. Superion Pain Management $212 5 payments
  9. IFUSE IMPLANT $205 2 payments
  10. Senza $196 3 payments
  11. Other $2,293 115 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

236

Median for Anesthesiology: 322

Drug cost

$4,909

Median for Anesthesiology: $8,738

Branded share of claims

14.8%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 35 $1,413
Tizanidine Hcl Generic 72 $878
Gabapentin Generic 42 $699
Pregabalin Generic 12 $576
Duloxetine Hcl Generic 12 $548
Diclofenac Sodium Generic 12 $290
Methocarbamol Generic 20 $262
Celecoxib Generic 31 $243

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$8,330

Of which drugs: $3

Medicare patients

16

Average age 71

Services billed

108

0 women, 16 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 0%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 11 35 $3

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

237 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record